Everolimus

Product NDC
70954-774
Requested package NDC
70954-774-20
11-digit product format
709540774
Labeler code
70954
Product ID
70954-774_ed7f01b0-3660-4785-a057-a32eea78d64b
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Everolimus
Dosage form
TABLET, FOR SUSPENSION
Route
ORAL
Labeler
ANI Pharmaceuticals, Inc.
Application
ANDA220597
Marketing category
ANDA
Marketing start
2025-10-10
Substance
EVEROLIMUS
Active strength
3 mg/1
Pharmacologic classes
Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC], mTOR Inhibitors [MoA]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A220597-001EVEROLIMUSEVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-09-21
A220597-002EVEROLIMUSEVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-09-21
A220597-003EVEROLIMUSEVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-09-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A220597-001AB
A220597-002AB
A220597-003AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A220597-001EVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-09-21d4dbc9d85df4…
2026-11-14 07:37:172026-10A220597-002EVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-09-21d4dbc9d85df4…
2026-11-14 07:37:172026-10A220597-003EVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-09-21d4dbc9d85df4…
2026-10-15 13:18:302026-09A220597-001EVEROLIMUS2MGTABLET, FOR SUSPENSION / ORALAB2026-09-21c2088c7a36db…
2026-10-15 13:18:302026-09A220597-002EVEROLIMUS3MGTABLET, FOR SUSPENSION / ORALAB2026-09-21c2088c7a36db…
2026-10-15 13:18:302026-09A220597-003EVEROLIMUS5MGTABLET, FOR SUSPENSION / ORALAB2026-09-21c2088c7a36db…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A220597-001AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A220597-002AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A220597-003AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A220597-001AB1c2088c7a36db…
2026-10-15 13:18:302026-09A220597-002AB1c2088c7a36db…
2026-10-15 13:18:302026-09A220597-003AB1c2088c7a36db…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

Additional Listing Data#

Finished product
Yes
Brand name base
Everolimus
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
EVEROLIMUS3 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
9HW64Q8G6GInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 3 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
1308428Internal RxNorm lookup
1308430Internal RxNorm lookup
1308432Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
ed7f01b0-3660-4785-a057-a32eea78d64bAvailable on FDA.report

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
EverolimusEVEROLIMUSANI Pharmaceuticals, Inc.ed7f01b0-3660-4785-a057-a32eea78d64b2026-09-24Warnings, Adverse reactionsExact identifier
application applno (ANDA): 220597
application number: ANDA220597
ndc (package): 70954-774-20
ndc (product): 70954-774
ndc11 (package): 70954077420

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startSampleExclude flagStatus
70954-774-207095407742028 BLISTER PACK in 1 CARTON (70954-774-20) / 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (70954-774-10) 28 blister pack2025-10-10NoNoCurrent